ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!OS Therapies Incorporated (OSTX) stock declined over -0.62%, trading at $1.61 on NYSE, down from the previous close of $1.62. The stock opened at $1.62, fluctuating between $1.54 and $1.67 in the recent session.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Employees | 3 |
Beta | -12.12 |
Sales or Revenue | N/A |
5Y Sales Change% | N/A |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com